BIOLASE (NASDAQ:BIOL) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOLFree Report) in a research note published on Monday morning. The brokerage issued a sell rating on the medical technology company’s stock.

BIOLASE Price Performance

Shares of BIOL opened at $0.19 on Monday. BIOLASE has a fifty-two week low of $0.13 and a fifty-two week high of $47.10. The firm has a market capitalization of $6.17 million, a PE ratio of -0.01 and a beta of 0.62. The company’s 50-day moving average is $0.34 and its 200-day moving average is $1.09. The company has a debt-to-equity ratio of 34.06, a current ratio of 1.26 and a quick ratio of 0.68.

Institutional Investors Weigh In On BIOLASE

Large investors have recently bought and sold shares of the company. Walleye Capital LLC acquired a new stake in shares of BIOLASE in the 2nd quarter valued at approximately $100,000. State Street Corp boosted its stake in shares of BIOLASE by 4.5% in the 1st quarter. State Street Corp now owns 436,076 shares of the medical technology company’s stock valued at $154,000 after purchasing an additional 18,682 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of BIOLASE by 222.5% in the 1st quarter. Renaissance Technologies LLC now owns 138,848 shares of the medical technology company’s stock valued at $39,000 after purchasing an additional 95,789 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of BIOLASE in the 2nd quarter valued at approximately $118,000. 8.79% of the stock is currently owned by institutional investors and hedge funds.

About BIOLASE

(Get Free Report)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.

Featured Articles

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.